Understanding autoimmune disease: new targets for drug discovery

Drug Discovery Today

Volumn 14, Issue 19-20, 2009, Pages 926-934

  Balagué, Cristina ^a   Kunkel, Steven L ^b   Godessart, Núria ^a  

^a Almirall Prodesfarma S A   (Spain)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; ABATACEPT; AIN 457; ALEMTUZUMAB; ARRY 438162; BELIMUMAB; CHEMOKINE RECEPTOR ANTAGONIST; CYTOKINE; DACLIZUMAB; DORAMAPIMOD; EPRATUZUMAB; FINGOLIMOD; HISTONE DEACETYLASE INHIBITOR; INCB 018424; INCB 28050; JANUS KINASE INHIBITOR; MED 545; MEDI 545; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; OCRELIZUMAB; PAMAPIMOD; RITUXIMAB; SCIO 469; TRAFFICET; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VORINOSTAT; VX 475; VX 702;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELIAC DISEASE; CLINICAL TRIAL; CROHN DISEASE; CUTANEOUS T CELL LYMPHOMA; CYTOKINE RELEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION REGULATION; GENE SILENCING; GLOMERULONEPHRITIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTE MIGRATION; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS VULGARIS; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TH17 CELL; ULCERATIVE COLITIS; UVEITIS;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; CELL MOVEMENT; CYTOKINES; DRUG DISCOVERY; EPIGENESIS, GENETIC; GENE THERAPY; HUMANS; IMMUNOLOGIC FACTORS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 70349316257     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.07.002     Document Type: Review

References (62)

1. Goodnow C.C., et al. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 425 (2005) 590-597
2. Cooper G.S., et al. The epidemiology of autoimmune diseases. Autoimmun. Rev. 2 (2003) 119-125
3. Hauser S.L. Multiple lessons for multiple sclerosis. N. Engl. J. Med. 359 (2008) 1838-1841
4. Calabrese L.H., et al. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann. Rheum. Dis. 67 Suppl 3 (2008) 64-65
5. Ramos-Casals M., et al. Autoimmune diseases induced by TNF-targeted therapies. Best Pract. Clin. Rheumatol. 22 (2008) 847-861
6. Nell V.P.K., et al. Benefit of early referral and very early therapy with disease modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 43 (2004) 906-914
7. Pelidou S.H., et al. Multiple sclerosis presented as clinically isolated syndrome: the need for early diagnosis and treatment. Ther. Clin. Risk Manage. 4 (2008) 627-630
8. Harrington L.E., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6 (2005) 1123-1132
9. Chen W., et al. Conversion of peripheral CD4+CD25-naïve T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198 (2003) 1875-1886
10. Veldhoen M., et al. Transforming growth factor-β "reprograms" the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat. Immunol. 12 (2008) 1341-1346
11. Zhu J., et al. CD4 T cells: fates, functions and faults. Blood 112 (2008) 1557-1568
12. O'Shea J.J., et al. T cell heterogeneity: firmly fixed, predominantly plastic or merely malleable?. Nat. Immunol. 9 (2008) 450-453
13. H cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat. Immunol. 3 (2002) 643-651
14. Koenen H.J., et al. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17 producing cells. Blood 112 (2008) 2340-2352
15. Strickland F.M., et al. Epigenetics in human autoimmunity. Epigenetics in autoimmunity-DNA methylation in systemic lupus erythematosus and beyond. Autoimmunity 41 (2008) 278-286
16. Cargill M., et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80 (2007) 273-290
17. Duerr R.H., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314 (2006) 1461-1463
18. Lubberts E., et al. Treatment with a neutralizing anti-murine IL-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50 (2004) 650-659
19. Uyttenhove C., et al. Development of an anti-IL-17A autovaccine that prevents experimental autoimmune encephalomyelitis. Eur. J. Immunol. 36 (2006) 2868-2874
20. Lowe C.E., et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphisms in the IL2RA region in type 1 diabetes. Nat. Genet. 39 (2007) 1074-1082
21. Dominguez C., et al. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr. Opin. Drug Discov. Dev. 8 (2005) 421-430
22. Schreiber S., et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 4 (2006) 325-334
23. Genovese M.C., et al. A randomized, double-blind, placebo-controlled phase 2 study of an oral p38α inhibitor SCIO-469 in patients with active rheumatoid arthritis. Presentation #715; American College of Rheumatology Meeting (2008)
24. Duraisamy S., et al. MK2: a novel molecular target for anti-inflammatory therapy. Expert. Opin. Ther. Targets 12 (2008) 921-936
25. Gavrin L.K., et al. Inhibition of Tpl2 kinase and TNF-alpha production with 1,7-naphthyridine-3-carbonitriles: synthesis and structure-activity relationships. Bioorg. Med. Chem. Lett. 15 (2005) 5288-5292
26. Pesu M., et al. Therapeutic targeting of Janus kinases. Immunol. Rev. 223 (2008) 132-142
27. Murray P.J. The JAK-STAT signalling pathway: input and output integration. J. Immunol. 178 (2007) 2623-2629
28. Plushner S.L. Tocilizumab: an interlukin-6 receptor inhibitor for the treatment of rheumatoid arthritis. Ann. Pharmacotherap. 42 (2008) 1660-1668
29. Moreland L. A randomized placebo-controlled study of INCB018424, a selective Janus kinase 1&2 inhibitor in rheumatoid arthritis. Presentation #74; American College of Rheumatology Meeting (2008). http://acr.confex.com/acr/2008/webprogram/Paper3281.html (http://acr.confex.com/acr/2008/webprogram/Paper3281.html)
30. Kremer J.M., et al. A randomized, double-blind, placebo-controlled trial of 3 dose levels of CP-690,550 versus placebo in the treatment of active rheumatoid arthritis. Presentation # L40; American College of Rheumatology Meeting (2006)
31. Wilkinson B. Co-administration of an oral JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis. Presentation #353; American College of Rheumatology Meeting (2008). http://acr.confex.com/acr/2008/webprogram/Paper3149.html (http://acr.confex.com/acr/2008/webprogram/Paper3149.html)
32. Godessart N., et al. Chemokines in autoimmune disease. Curr. Opin. Immunol. 13 (2001) 670-675
33. Bonecchi R., et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 187 (1998) 129-134
34. Godessart N. Chemokine receptors: attractive targets for drug discovery. Ann. NY Acad. Sci. 1051 (2005) 647-657
35. Acosta-Rodriguez E.V., et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8 (2007) 639-646
36. Yamazaki T., et al. CCR6 regulates the migration of inflammatory and regulatory T cells. J. Immunol. 181 (2008) 8391-8401
37. Ebert L.M., et al. Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol. Immunol. 42 (2005) 799-809
38. Rückle T., et al. PI3Kγ inhibition: towards an "aspirin" of the 21st century. Nat. Rev. Drug Discov. 5 (2006) 903-918
39. Sasaki T., et al. Function of PI3K γ in thymocyte development, T cell activation, and neutrophil migration. Science 287 (2000) 1040-1046
40. Romme C., et al. PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond?. Nat. Rev. Immunol. 7 (2007) 191-201
41. Barber D., et al. PI3Kgamma inhibition blocks gromerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 11 (2005) 933-935
42. Mehling M., et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 71 (2008) 1261-1267
43. Garber K. Infections cast cloud over Novartiś MS therapy. Nat. Biotechnol. 26 (2008) 844-845
44. Pappas C., et al. LX2931: a potential small molecule treatment for autoimmune disorders. Presentation #351, American College of Rheumatology Meeting (2008). http://acr.confex.com/acr/2008/webprogram/Paper3021.html (http://acr.confex.com/acr/2008/webprogram/Paper3021.html)
45. Fraussen J., et al. B cell characterization and reactivity analysis in multiple sclerosis. Autoimmun. Rev. (2009) 10.1016/j.autrev.2009.02.030
46. Tsirogianni A., et al. Pipi E, Soufleros K. Specificity of islet cell autoantibodies and coexistence with other organ specific autoantibodies in type 1 diabetes mellitus. Autoimmun. Rev. (2009) 10.1016/j.autrev.2009.02.019
47. Adamus G. (200) Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun. Rev. 8 (2009) 410-414
48. Strand V., et al. Biologic therapies in rheumatology: lessons learned, future directions. Nat. Rev. Drug Discov. 6 (2007) 75-92
49. Gross J.A., et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 15 (2001) 289-291
50. Costello K., et al. Cladribine tablet's potential in multiple sclerosis treatment. J. Neurosci. Nurs. 40 (2008) 275-280
51. Hirst C.L., et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J. Neurol. 255 (2008) 231-238
52. Chen Z., et al. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin. Immunol. 19 (2007) 400-408
53. Liao J.J., et al. Cutting edge: alternative signalling of Th17 development by sphingosine 1-phosphate. J. Immunol. 178 (2007) 5425-5428
54. Beissert S., et al. Regulatory T cells. J. Invest Dermatol. 126 (2006) 15-24
55. Strom T.B., et al. Ctyokine related therapies for autoimmune disease. Curr. Opin. Immunol. 20 (2008) 676-681
56. Delgado J. Novel epigenetic targets in lymphoproliferative disorders. Curr. Cancer Drug Targets 8 (2008) 378-391
57. Rigby R., et al. Silencing SLE: the power and promise of small noncoding RNAs. Curr. Opin. Rheum. 20 (2008) 526-531
58. Ansel K.M., et al. Regulation of Th2 differentiation and il4 locus accessibility. Annu. Rev. Immunol. 24 (2006) 607-656
59. Garber K. HDAC inhibitors overcome first hurdle. Nat. Biotechnol. 25 (2007) 17-19
60. Merkenschlager M., et al. RNAi and chromatin in T cell development and function. Curr. Opin. Immunol. 20 (2008) 131-138
61. Wang Y., et al. MicroRNA epigenetic alterations: predicting biomarkers and therapeutic targets in human diseases. Clin. Genet. 74 (2008) 307-315
62. Xiao Ch., et al. Lymphoproliferative disease and autoimmunity in mice with increased mi-R-17-92 expression in lymphocytes. Nat. Immunol. 4 (2008) 405-414